Poor
Not Aligned
Patient Risk:
Low
Summary
Most claims are non-label statements about patents/exclusivity/third-party organizations or generic regulatory process. The provided Lipitor prescribing information excerpts do not support these claims, and several assertions are therefore unsupported relative to the supplied label text.
Category Scores
Accurate Statements
The active ingredient in Lipitor is atorvastatin calcium (atorvastatin).
Supported by the provided label excerpt indicating Lipitor contains atorvastatin calcium (e.g., Section 3: “White, elliptical, film-coated tablets containing 10, 20, 40, and 80 mg atorvastatin calcium.”).
Unsupported Statements
Lipitor has been available in generic versions since 2012.
No support in the provided prescribing information excerpts regarding generic availability dates.
The original Lipitor patent held by Pfizer expired in 2011.
No support in the provided prescribing information excerpts regarding patent expiration dates or Pfizer’s patent status.
To approve generic versions of Lipitor, manufacturers must demonstrate their products are bioequivalent to the original Lipitor formulation.
No support in the provided prescribing information excerpts regarding generic approval requirements (bioequivalence).
Generic Lipitor must have the same active ingredient, at the same dosage strength, and with the same therapeutic effect as brand-name Lipitor.
The provided prescribing information excerpts do not state requirements for generic products or therapeutic-effect equivalence.
The FDA states that a generic drug must contain the same active ingredient, dosage form, and strength as the innovator drug.
No support in the provided prescribing information excerpts for FDA statements on generic substitution/requirements.
The FDA states that generic drugs must be manufactured to the same standards as the innovator drug.
No support in the provided prescribing information excerpts.
The active ingredient in generic Lipitor is the same as in brand-name Lipitor.
No support in the provided prescribing information excerpts regarding generic product composition.
Generic Lipitor may differ from brand-name Lipitor in inactive ingredients, manufacturing process, or packaging.
No support in the provided prescribing information excerpts.
Differences in inactive ingredients, manufacturing process, or packaging between generic and brand-name Lipitor are typically minor and do not affect the efficacy of the medication.
No support in the provided prescribing information excerpts.
The American Heart Association states that generic medications are chemically identical to brand-name medications and have the same therapeutic effects.
No support in the provided prescribing information excerpts (and no AHA statements are included).
Teva Pharmaceuticals manufactures generic versions of Lipitor.
No support in the provided prescribing information excerpts regarding specific manufacturers of generics.
Ranbaxy Pharmaceuticals manufactures generic versions of Lipitor.
No support in the provided prescribing information excerpts regarding specific manufacturers of generics.
Mylan Pharmaceuticals manufactures generic versions of Lipitor.
No support in the provided prescribing information excerpts regarding specific manufacturers of generics.
Apotex manufactures generic versions of Lipitor.
No support in the provided prescribing information excerpts regarding specific manufacturers of generics.
Pfizer continued to hold other patents and exclusivities related to Lipitor after the original patent expired in 2011.
No support in the provided prescribing information excerpts regarding Pfizer’s continuing patent/exclusivity status.
In 2012, the FDA granted Pfizer 6-month exclusivity for a reformulation of Lipitor.
No support in the provided prescribing information excerpts.
The Lipitor patents listed by DrugPatentWatch.com include US Patent 8,435,468 (expired).
No support in the provided prescribing information excerpts, and patent-listing sources are not included.
The Lipitor patents listed by DrugPatentWatch.com include US Patent 8,435,469 (expired).
No support in the provided prescribing information excerpts.
The Lipitor patents listed by DrugPatentWatch.com include US Patent 8,435,470 (expired).
No support in the provided prescribing information excerpts.
Contradictions
Important Omissions
No label-based discussion of Lipitor’s FDA-approved indications, dosage, contraindications, warnings/precautions, drug interactions, adverse reactions, or monitoring is present in the claims provided (only generic/patent/manufacturer statements are included).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The unsupported claims are primarily about generic availability, patent/exclusivity, and manufacturers rather than dosing, contraindications, or safety-relevant prescribing details found in the provided label excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Most statements are not supported by the provided Lipitor prescribing information excerpts; they rely on external patent/generic-regulatory assertions and third-party organizations/manufacturers not present in the label text.
Suggested Improvement
Limit claims to information explicitly present in the provided prescribing information (e.g., active ingredient/formulation) and remove or clearly separate non-label patent/generic-market assertions unless the label excerpts provided include that content.